Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
In this randomized controlled phase III study the investigators will evaluate whether TIL
infusion preceded by non-myeloablative chemotherapy and followed by high dose bolus
interleukin-2 can result in an improved progression free survival when randomly compared to
ipilimumab in 168 stage IV melanoma patients. A health technology assessment (HTA) will be
performed to evaluate the impact of the TIL treatment on patients and organizational
processes and cost-effectivity.
Phase:
Phase 3
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborators:
Copenhagen University Hospital at Herlev University of Manchester